Want to see LXEO full AI Analyst Report?
LXEO Stock Chart & Stats
$6.91
-$0.29(-4.02%)
At close: 4:00 PM EST
$6.91
-$0.29(-4.02%)
Day’s Range― - ―
52-Week Range$3.60 - $10.99
Previous CloseN/A
Volume22.32K
Average Volume (3M)888.14K
Market Cap
$396.53M
Enterprise Value$326.63M
Total Cash (Recent Filing)$71.77M
Total Debt (Recent Filing)$7.37M
Price to Earnings (P/E)―
Beta2.25
Next Earnings
Aug 19, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.45
Shares Outstanding78,521,640
10 Day Avg. Volume979,330
30 Day Avg. Volume888,137
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)2.16
Price to Sales (P/S)0.00
P/FCF Ratio-5.38
Enterprise Value/Market Cap0.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-598.23
Enterprise Value/Ebitda-3.83
Forecast
1Y Price Target
$15.75Price Target Upside127.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.16
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biopsy Biomarker ConfirmationBiopsy results showing increased PKP2 protein indicate target engagement and support biological activity, strengthening the rationale for further clinical evaluation.
Strategic Collaboration CredibilityAnalyst's buy recommendation notes that a strategic collaboration with Johnson & Johnson enhances credibility of the cardiac gene therapy platform and supports longer-term value potential.
Valuation Support From Existing AssetsThe company's established program provides a valuation floor that can limit downside and sustain investor interest if early PKP2 results are mixed or safety-limited.
Bears Say
Inconsistent Multi-metric EfficacyKey arrhythmia measures have not reliably improved within the same patients, raising concern that averaged results may hide inconsistent individual responses across cardiac markers.
Medication Confounding In Small StudiesBackground use or changes of anti-arrhythmic medications in small cohorts can create the appearance of efficacy, complicating assessment of the true drug benefit without adjustment for medication effects.
Safety Risk And Binary Investor ReactionA new or worsening safety signal or continued absence of a coherent efficacy pattern across cardiac measures would erode the investment thesis and likely increase volatility as investors revert valuation toward existing assets.
Lexeo Therapeutics, Inc. News
LXEO FAQ
What was Lexeo Therapeutics, Inc.’s price range in the past 12 months?
Lexeo Therapeutics, Inc. lowest stock price was $3.60 and its highest was $10.99 in the past 12 months.
What is Lexeo Therapeutics, Inc.’s market cap?
Lexeo Therapeutics, Inc.’s market cap is $396.53M.
When is Lexeo Therapeutics, Inc.’s upcoming earnings report date?
Lexeo Therapeutics, Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 39 days.
How were Lexeo Therapeutics, Inc.’s earnings last quarter?
Lexeo Therapeutics, Inc. released its earnings results on May 11, 2026. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.309 by $0.059.
Is Lexeo Therapeutics, Inc. overvalued?
According to Wall Street analysts Lexeo Therapeutics, Inc.’s price is currently Undervalued.
Does Lexeo Therapeutics, Inc. pay dividends?
Lexeo Therapeutics, Inc. does not currently pay dividends.
What is Lexeo Therapeutics, Inc.’s EPS estimate?
Lexeo Therapeutics, Inc.’s EPS estimate is -0.29.
How many shares outstanding does Lexeo Therapeutics, Inc. have?
Lexeo Therapeutics, Inc. has 78,521,640 shares outstanding.
What happened to Lexeo Therapeutics, Inc.’s price movement after its last earnings report?
Lexeo Therapeutics, Inc. reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.309. Following the earnings report the stock price went up 4.974%.
Which hedge fund is a major shareholder of Lexeo Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LXEO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lexeo Therapeutics, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.75 (127.93% Upside)
$15.75 (127.93% Upside)
Blogger Sentiment
Bullish
LXEO Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 603.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $280.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
9.78%
12-Months-Change
Fundamentals
Return on Equity
-47.48%
Trailing 12-Months
Asset Growth
99.19%
Trailing 12-Months
Company Description
Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
LXEO Stock 12 Month Forecast
Average Price Target
$15.75
▲(127.93% Upside)
Technical Analysis
Tvardi Therapeutics
―
Larimar Therapeutics
―
Capricor Therapeutics
―
Benitec Biopharma
―
Diamedica Therapeutics
―
Ownership Overview
1.19% Insiders
8.79% Mutual Funds
0.34% Other Institutional Investors
75.49% Public Companies and
Individual Investors